Title: Identifying markers for the schizophrenia syndrome

**Abstract**

Psychiatry is one of the few areas of medicine that does not have an array of diagnostic tests at its disposal. Part of the reason for this deficit is the complexity of the disorders being dealt with; therefore diagnosis, treatment and recovery management all depend heavily on the knowledge and experience of the treating clinician. In order to support this expertise, a great deal of effort is being invested in the quest for biomarkers for different aspects of the disorders such as diagnosis, stratification for treatment and assessing treatment responsivity.

Over the decades, countless studies have assessed the levels of gene expression in the form of messenger RNA levels in samples from people with psychiatric disorders, particularly schizophrenia. However, until recently (1), few investigators have attempted to assess the potential of this data for use as biomarkers.

Our recent microarray study, using post-mortem brain tissue from people with schizophrenia and people with no history of psychiatric illness was analysed using a range of predictive models. At the first level the modelling was used to distinguish samples from people with schizophrenia from the control group. A series of 100 markers was identified that achieved this goal with an overall accuracy of up to 1.0. The validity of these markers has been assessed in two separate cohorts of samples from people with schizophrenia and control subjects. The second level of analysis was to determine whether a similar approach could be used to separate the subjects with schizophrenia into two distinct subgroups -- one with low levels of muscarinic M1 receptors and the other with levels of muscarinic M1 receptors similar to those seen in control subjects. A battery of 97 markers achieved this with an overall accuracy of up to 1.0.

The uses of these potential biomarkers are quite different. The first will be of most use in people who are in the prodromal phase of the disorder -- facilitating their rapid identification and subsequent therapeutic program. The second set of markers will be useful for the stratification of people, initially for clinical trials of the selective M1 ligands that are currently in development and, once these drugs are available, for the identification of people who will most benefit from such targeted therapy.
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